EA200801245A1 - [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними - Google Patents

[4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними

Info

Publication number
EA200801245A1
EA200801245A1 EA200801245A EA200801245A EA200801245A1 EA 200801245 A1 EA200801245 A1 EA 200801245A1 EA 200801245 A EA200801245 A EA 200801245A EA 200801245 A EA200801245 A EA 200801245A EA 200801245 A1 EA200801245 A1 EA 200801245A1
Authority
EA
Eurasian Patent Office
Prior art keywords
forms
thrombosis
compounds
pharmaceutically acceptable
formula
Prior art date
Application number
EA200801245A
Other languages
English (en)
Other versions
EA017402B1 (ru
Inventor
Роберт М. Скарборо
Волин Хуанг
Мукунд Мехротра
Ксиаоминг Чжанг
Хилари Кэннон
Крейг М. Грант
Original Assignee
Портола Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Портола Фармасьютикалз, Инк. filed Critical Портола Фармасьютикалз, Инк.
Publication of EA200801245A1 publication Critical patent/EA200801245A1/ru
Publication of EA017402B1 publication Critical patent/EA017402B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к новым сульфонилмочевинам формулы (I) и их фармацевтически приемлемым производным и их полиморфньм и аморфным формам. Соединения в их различных формах являются эффективными ингибиторами АДФ-рецепторов тромбоцитов и могут использоваться в различных фармацевтических композициях и являются особенно эффективными для предупреждения и/или лечения сердечно-сосудистых заболеваний, в частности, заболеваний, связанных с тромбозом. Изобретение также относится к способу получения таких соединений и форм и способу предупреждения или лечения тромбоза и связанных с тромбозом состояний у млекопитающего, включающему стадию введения терапевтически эффективного количества соединения формулы (I) или его фармацевтически приемлемой соли или их форм.
EA200801245A 2005-11-03 2006-11-03 [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение EA017402B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73365005P 2005-11-03 2005-11-03
PCT/US2006/043093 WO2007056219A2 (en) 2005-11-03 2006-11-03 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Publications (2)

Publication Number Publication Date
EA200801245A1 true EA200801245A1 (ru) 2008-10-30
EA017402B1 EA017402B1 (ru) 2012-12-28

Family

ID=38023842

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801245A EA017402B1 (ru) 2005-11-03 2006-11-03 [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение

Country Status (21)

Country Link
US (3) US20070208045A1 (ru)
EP (2) EP1951254B1 (ru)
JP (1) JP5509406B2 (ru)
KR (1) KR101423483B1 (ru)
CN (1) CN101300013B (ru)
AR (1) AR056762A1 (ru)
AT (1) ATE540034T1 (ru)
AU (1) AU2006311795B2 (ru)
BR (1) BRPI0618210A2 (ru)
CA (1) CA2627719C (ru)
CY (1) CY1112826T1 (ru)
DK (1) DK1951254T3 (ru)
EA (1) EA017402B1 (ru)
ES (1) ES2380814T3 (ru)
HK (1) HK1121051A1 (ru)
IL (1) IL191193A (ru)
NZ (2) NZ567747A (ru)
PT (1) PT1951254E (ru)
TW (2) TW200728260A (ru)
WO (2) WO2007056167A2 (ru)
ZA (1) ZA200804241B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565437A1 (en) 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
NZ567747A (en) * 2005-11-03 2011-11-25 Portola Pharm Inc [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
KR20090010098A (ko) 2006-05-05 2009-01-28 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 저해제
WO2008133155A1 (ja) 2007-04-19 2008-11-06 Astellas Pharma Inc. 二環式ヘテロ環化合物
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
ES2467468T3 (es) * 2007-05-02 2014-06-12 Portola Pharmaceuticals, Inc. Terapia de combinación con un compuesto que actúa como inhibidor del receptor de ADP plaquetario
KR20100029746A (ko) 2007-05-02 2010-03-17 포톨라 파마슈티컬스, 인코포레이티드 직접 작용하는 가역적인 ｐ2ｙ12 억제제의 정맥내 및 경구 투여
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
EP2167487B1 (en) * 2007-06-18 2015-02-18 Sanofi Pyrrole derivatives as p2y12 antagonists
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
CN102271663A (zh) * 2008-11-14 2011-12-07 波托拉医药品公司 控制释放在低pH下水溶性差的可电离活性药物的固体组合物及其用法
WO2011006169A1 (en) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2
JP5597202B2 (ja) 2009-08-28 2014-10-01 第一三共株式会社 ３−（ビアリールオキシ）プロピオン酸誘導体
WO2011084652A2 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
US8987285B2 (en) * 2010-12-03 2015-03-24 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
RU2556198C1 (ru) * 2014-04-10 2015-07-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Способ профилактики развития постперикардиотомного синдрома у больных ишемической болезнью сердца, подвергшихся коронарному шунтированию
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE845042C (de) 1950-07-14 1952-07-28 Basf Ag Verfahren zur Herstellung von Sulfonylurethanen, -harnstoffen oder -carbonsaeureamiden
US3847925A (en) 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
US5314902A (en) 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6268380B1 (en) 1993-02-19 2001-07-31 G. D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
AU6395094A (en) 1993-03-15 1994-10-11 G.D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
JPH0881442A (ja) 1994-07-14 1996-03-26 Otsuka Pharmaceut Co Ltd 環状アミド誘導体
TW448161B (en) 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
US6413724B1 (en) * 1996-10-28 2002-07-02 Versicor, Inc. Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
US6160000A (en) 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
JPH10195323A (ja) 1997-01-09 1998-07-28 Nippon Paper Ind Co Ltd 新規なスルホニルグアニジン化合物及びそれを用いた感熱記録体
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
EP1047699A1 (en) 1998-01-15 2000-11-02 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
JP2000204081A (ja) 1998-02-05 2000-07-25 Takeda Chem Ind Ltd スルホンアミド誘導体、その製造法及び用途
DE60114994T2 (de) 2000-02-04 2006-08-03 Portola Pharmaceuticals, Inc., South San Francisco Blutplättchen-adp-rezeptor-inhibitoren
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DE60144284D1 (de) * 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
JP2005523249A (ja) 2002-01-09 2005-08-04 エンズレル インコーポレイテッド 多環式芳香族抗酸化剤または抗炎症化合物のリポソーム薬物配達
US20040242658A1 (en) * 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
US7109332B2 (en) * 2003-10-03 2006-09-19 Portola Pharmaceuticals, Inc. 2,4-dioxo-3-quinazolinylaryl sulfonylureas
NZ567747A (en) 2005-11-03 2011-11-25 Portola Pharm Inc [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
KR20100029746A (ko) * 2007-05-02 2010-03-17 포톨라 파마슈티컬스, 인코포레이티드 직접 작용하는 가역적인 ｐ2ｙ12 억제제의 정맥내 및 경구 투여
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

Also Published As

Publication number Publication date
US20070208045A1 (en) 2007-09-06
CN101300013A (zh) 2008-11-05
HK1121051A1 (ru) 2009-04-17
AU2006311795A1 (en) 2007-05-18
EP1951254B1 (en) 2012-01-04
EP1951254A2 (en) 2008-08-06
AU2006311795B2 (en) 2013-01-17
ES2380814T3 (es) 2012-05-18
JP2009515836A (ja) 2009-04-16
TW200728260A (en) 2007-08-01
PT1951254E (pt) 2012-04-12
EP2428514A1 (en) 2012-03-14
CN101300013B (zh) 2012-11-28
CY1112826T1 (el) 2016-02-10
EA017402B1 (ru) 2012-12-28
WO2007056219A3 (en) 2007-12-27
WO2007056167A3 (en) 2007-10-04
TWI397529B (zh) 2013-06-01
WO2007056219A2 (en) 2007-05-18
KR20080071167A (ko) 2008-08-01
BRPI0618210A2 (pt) 2011-08-23
US20120088736A1 (en) 2012-04-12
TW200804356A (en) 2008-01-16
NZ596025A (en) 2013-08-30
EP1951254A4 (en) 2009-05-27
ZA200804241B (en) 2009-09-30
NZ567747A (en) 2011-11-25
AR056762A1 (es) 2007-10-24
ATE540034T1 (de) 2012-01-15
WO2007056167A2 (en) 2007-05-18
DK1951254T3 (da) 2012-05-07
CA2627719A1 (en) 2007-05-18
JP5509406B2 (ja) 2014-06-04
CA2627719C (en) 2016-07-12
US8058284B2 (en) 2011-11-15
KR101423483B1 (ko) 2014-07-28
US20070123547A1 (en) 2007-05-31
IL191193A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
EA200801245A1 (ru) [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними
DE60114994D1 (de) Blutplättchen-adp-rezeptor-inhibitoren
EA200500814A1 (ru) Производные пирролопиримидина
ATE517882T1 (de) Chinolinderivate
ATE485290T1 (de) Platelet adp rezeptor inhibitoren
WO2006124692A3 (en) 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
NO20080187L (no) Aspartylproteaseinhibitorer
MY137509A (en) Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
WO2006119507A3 (en) Non-nucleotide composition and method for inhibiting platelet aggregation
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
WO2008008539A3 (en) Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
WO2009155121A3 (en) Inhibitors of pi3 kinase
NO20090144L (no) Heterosykliske aspartylproteaseinhibitorer
NO20063928L (no) Substituerte kinolinforbindelser
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
EA200900821A1 (ru) Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU